Beyond the danger signal: RNA aggregates orchestrate immunotherapy
- PMID: 38866645
- DOI: 10.1016/j.molmed.2024.05.018
Beyond the danger signal: RNA aggregates orchestrate immunotherapy
Abstract
Mendez-Gomez et al. recently demonstrated the transformative potential of RNA-lipid particle aggregates (RNA-LPAs) in immunotherapy. By reprogramming the tumor microenvironment (TME) and potentiating antitumor immunity, RNA-LPAs target primary tumors and elicit robust systemic immunity. This innovative platform holds promise for translating preclinical success into tangible clinical benefits.
Keywords: cancer vaccine; immunotherapy; lipid particle aggregates (LPAs); mRNA; tumor microenvironment (TME).
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Interests The authors declare no competing interests.
Similar articles
-
RNA aggregates harness the danger response for potent cancer immunotherapy.Cell. 2024 May 9;187(10):2521-2535.e21. doi: 10.1016/j.cell.2024.04.003. Epub 2024 May 1. Cell. 2024. PMID: 38697107 Free PMC article.
-
mRNA aggregates harness danger response for potent cancer immunotherapy.medRxiv [Preprint]. 2023 Mar 17:2023.03.12.23287108. doi: 10.1101/2023.03.12.23287108. medRxiv. 2023. Update in: Cell. 2024 May 9;187(10):2521-2535.e21. doi: 10.1016/j.cell.2024.04.003. PMID: 36993772 Free PMC article. Updated. Preprint.
-
Systemic immunity in cancer.Nat Rev Cancer. 2021 Jun;21(6):345-359. doi: 10.1038/s41568-021-00347-z. Epub 2021 Apr 9. Nat Rev Cancer. 2021. PMID: 33837297 Free PMC article. Review.
-
Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment.Front Biosci (Landmark Ed). 2024 Oct 8;29(10):349. doi: 10.31083/j.fbl2910349. Front Biosci (Landmark Ed). 2024. PMID: 39473401 Review.
-
Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy.BMB Rep. 2024 Sep;57(9):388-399. doi: 10.5483/BMBRep.2024-0031. BMB Rep. 2024. PMID: 38919017 Free PMC article. Review.
Cited by
-
Next-Generation Tumor Targeting with Genetically Engineered Cell Membrane-Coated Nanoparticles.Biodes Res. 2024 Oct 25;6:0055. doi: 10.34133/bdr.0055. eCollection 2024. Biodes Res. 2024. PMID: 39464390 Free PMC article. Review. No abstract available.
-
Eclipsing Toxicity, Enhancing Efficacy: Clofazimine's Vanguard in the Realm of Anti-PD-1 and CTLA-4 Immunotherapy.Research (Wash D C). 2024 Jul 9;7:0419. doi: 10.34133/research.0419. eCollection 2024. Research (Wash D C). 2024. PMID: 39156659 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical